Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 67Pancreatic Neoplasms 34Neoplasm Metastasis 22Neuroblastoma 21Neoplasms 16Colonic Neoplasms 15Stomach Neoplasms 13Rectal Neoplasms 13Sarcoma, Ewing 8Rhabdomyosarcoma 8Esophageal Squamous Cell Carcinoma 8Small Cell Lung Carcinoma 7Sarcoma 7Ovarian Neoplasms 6Lung Neoplasms 6Cholangiocarcinoma 6Esophageal Neoplasms 5Breast Neoplasms 5Adenocarcinoma Of Esophagus 5Medulloblastoma 4Gastrointestinal Neoplasms 4Endometrial Neoplasms 4Biliary Tract Neoplasms 4Adenocarcinoma 4Recurrence 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Osteosarcoma 3Glioma 3Glioblastoma 3Ganglioneuroblastoma 3

Interventions

Pharmaceutical Preparations 1Irinotecan 1Fluorouracil 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
BRAF V600 Colorectal Cancer × Irinotecan × 1 year × Clear all
NCT07150247 2025-09-26

Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer

Sun Yat-sen University

Phase 2 Recruiting
20 enrolled
Gastrointestinal

BRAF V600 Colorectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡